U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H18N4O3
Molecular Weight 278.3075
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PENTOXIFYLLINE

SMILES

CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O

InChI

InChIKey=BYPFEZZEUUWMEJ-UHFFFAOYSA-N
InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C13H18N4O3
Molecular Weight 278.3075
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Pentoxil (Pentoxifylline Extended-release Tablets, USP) is indicated for the treatment of patients with intermittent claudication based on chronic occlusive arterial disease of the limbs. Pentoxil can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. Pentoxifylline and its metabolites improve the flow properties of blood by decreasing its viscosity. In patients with chronic peripheral arterial disease, this increases blood flow to the affected microcirculation and enhances tissue oxygenation. The precise mode of action of pentoxifylline and the sequence of events leading to clinical improvement are still to be defined. Pentoxifylline inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, pentoxifylline also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity. It is also a non-selective adenosine receptor antagonist. Pentoxifylline administration has been shown to produce dose-related hemorrheologic effects, lowering blood viscosity, and improving erythrocyte flexibility. Pentoxifylline has been shown to increase leukocyte deformability and to inhibit neutrophil adhesion and activation. Tissue oxygen levels have been shown to be significantly increased by therapeutic doses of pentoxifylline in patients with peripheral arterial disease. Clinical trials were conducted using either extended-release pentoxifylline tablets for up to 60 weeks or immediate-release pentoxifylline capsules for up to 24 weeks. Dosage ranges in the tablet studies were 400 mg bid to tid and in the capsule studies, 200-400 mg tid. The incidence of adverse reactions was higher in the capsule studies (where dose related increases were seen in digestive and nervous system side effects) than in the tablet studies. Studies with the capsule include domestic experience, whereas studies with the extended-release tablets were conducted outside the U.S.

CNS Activity

Curator's Comment:: Pentoxifylline readily crosses the blood-brain barrier, so systemically administered drug might reduce both circulating and brain levels of pro-inflammatory cytokines

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PENTOXIL

Approved Use

INDICATIONS & USAGE Pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease.

Launch Date

9.2283837E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1607 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTOXIFYLLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
272 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTOXIFYLLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
683 ng/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTOXIFYLLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
719 ng/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTOXIFYLLINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1228 ng × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTOXIFYLLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
193 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTOXIFYLLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
380 ng × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTOXIFYLLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4842 ng × h/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTOXIFYLLINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.84 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTOXIFYLLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.48 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTOXIFYLLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
0.39 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PENTOXIFYLLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
80 mg/kg single, oral
Overdose
Dose: 80 mg/kg
Route: oral
Route: single
Dose: 80 mg/kg
Sources:
unhealthy, adult and children
n = 44
Health Status: unhealthy
Condition: peripheral vascular disease
Age Group: adult and children
Sex: unknown
Population Size: 44
Sources:
Disc. AE: Flushing, Hypotension...
AEs leading to
discontinuation/dose reduction:
Flushing (44 patients)
Hypotension (44 patients)
Convulsions (44 patients)
Somnolence (44 patients)
Loss of consciousness (44 patients)
Fever (44 patients)
Agitation (44 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Agitation 44 patients
Disc. AE
80 mg/kg single, oral
Overdose
Dose: 80 mg/kg
Route: oral
Route: single
Dose: 80 mg/kg
Sources:
unhealthy, adult and children
n = 44
Health Status: unhealthy
Condition: peripheral vascular disease
Age Group: adult and children
Sex: unknown
Population Size: 44
Sources:
Convulsions 44 patients
Disc. AE
80 mg/kg single, oral
Overdose
Dose: 80 mg/kg
Route: oral
Route: single
Dose: 80 mg/kg
Sources:
unhealthy, adult and children
n = 44
Health Status: unhealthy
Condition: peripheral vascular disease
Age Group: adult and children
Sex: unknown
Population Size: 44
Sources:
Fever 44 patients
Disc. AE
80 mg/kg single, oral
Overdose
Dose: 80 mg/kg
Route: oral
Route: single
Dose: 80 mg/kg
Sources:
unhealthy, adult and children
n = 44
Health Status: unhealthy
Condition: peripheral vascular disease
Age Group: adult and children
Sex: unknown
Population Size: 44
Sources:
Flushing 44 patients
Disc. AE
80 mg/kg single, oral
Overdose
Dose: 80 mg/kg
Route: oral
Route: single
Dose: 80 mg/kg
Sources:
unhealthy, adult and children
n = 44
Health Status: unhealthy
Condition: peripheral vascular disease
Age Group: adult and children
Sex: unknown
Population Size: 44
Sources:
Hypotension 44 patients
Disc. AE
80 mg/kg single, oral
Overdose
Dose: 80 mg/kg
Route: oral
Route: single
Dose: 80 mg/kg
Sources:
unhealthy, adult and children
n = 44
Health Status: unhealthy
Condition: peripheral vascular disease
Age Group: adult and children
Sex: unknown
Population Size: 44
Sources:
Loss of consciousness 44 patients
Disc. AE
80 mg/kg single, oral
Overdose
Dose: 80 mg/kg
Route: oral
Route: single
Dose: 80 mg/kg
Sources:
unhealthy, adult and children
n = 44
Health Status: unhealthy
Condition: peripheral vascular disease
Age Group: adult and children
Sex: unknown
Population Size: 44
Sources:
Somnolence 44 patients
Disc. AE
80 mg/kg single, oral
Overdose
Dose: 80 mg/kg
Route: oral
Route: single
Dose: 80 mg/kg
Sources:
unhealthy, adult and children
n = 44
Health Status: unhealthy
Condition: peripheral vascular disease
Age Group: adult and children
Sex: unknown
Population Size: 44
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
likely (co-administration study)
Comment: Concomitant administration of strong CYP1A2 inhibitors (including e.g. ciprofloxacin or fluvoxamine) may increase the exposure to pentoxifylline
Page: 7.0
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Immunotherapy of inflammatory demyelinating diseases of the central nervous system.
2001
Indobufen: an updated review of its use in the management of atherothrombosis.
2001
Microvascular endothelial dysfunction: a renewed appreciation of sepsis pathophysiology.
2001
The alveolar septal thickness and type II pneumocytes number in irradiated lungs, time expression and the effect of pentoxifylline.
2001
Managing cancer-related anorexia/cachexia.
2001
The efficacy of medication on tinnitus due to acute acoustic trauma.
2001
New treatment options in intermittent claudication: the US experience.
2001 Apr
Cilostazol: a novel treatment option in intermittent claudication.
2001 Apr
[Effect of pentoxifylline on promoter activity of human alpha 1(I) procollagen gene].
2001 Apr
Successful combination therapy--flunarizine, pentoxifylline, and cholestyramine--for spur cell anemia.
2001 Apr
A new treatment for peripheral arterial disease.
2001 Apr
Methylxanthine sensitization of human colon cancer cells to 186Re-labeled monoclonal antibody.
2001 Apr
Pentoxifylline reduces coronary leukocyte accumulation early in reperfusion after cold ischemia.
2001 Apr
Prevention of compartment syndrome in dorsal root ganglia caused by exposure to nucleus pulposus.
2001 Apr 15
A pilot study of pentoxifylline in the treatment of radiation-induced trismus.
2001 Aug
Administration of pentoxifylline during allergen sensitization dissociates pulmonary allergic inflammation from airway hyperresponsiveness.
2001 Aug 1
Cytokine-mediated suppression of cytochrome P450 1A1 in Hepa-1c1c7 cells by pokeweed mitogen.
2001 Feb 28
Prognostic value of electromyography in acute peripheral facial nerve palsy.
2001 Jan
Intravenous pentoxifylline does not enhance the pulmonary haemodynamic efficacy of frusemide in strenuously exercising thoroughbred horses.
2001 Jul
Ibudilast attenuates astrocyte apoptosis via cyclic GMP signalling pathway in an in vitro reperfusion model.
2001 Jul
Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loosening of total joint components.
2001 Jul
Renal failure, anaemia, cytokines and inflammation.
2001 Jul
Pentoxifylline improves in vitro fertilization and subsequent development of bovine oocytes.
2001 Jul 15
Management of patients with severe oral mucosal disease.
2001 Jul-Aug
The role of glucose in supporting motility and capacitation in human spermatozoa.
2001 Jul-Aug
A redox-regulated tyrosine phosphorylation cascade in rat spermatozoa.
2001 Jul-Aug
Effect of pentoxifylline on nitrogen balance and 3-methylhistidine excretion in parenterally fed endotoxemic rats.
2001 Jul-Aug
Medical management of peripheral arterial disease.
2001 Jul-Aug
Improved response of colon cancer xenografts to radioimmunotherapy with pentoxifylline treatment.
2001 Jun
[Effect of pentoxifylline on the healing of experimental anastomosis of the left colon in rats].
2001 Jun
Pentoxifylline rescue preserves lung function in isolated canine lungs injured with phorbol myristate acetate.
2001 Jun
Pentoxifylline effects on acute and late complications after radiotherapy in rabbit.
2001 Jun
Therapeutic effects of Vascupump treatment patients with Fontaine Stage II B arteriopathy.
2001 Jun
Countervailing influence of tumor necrosis factor-alpha and nitric oxide in endotoxemia.
2001 Jun
Intermittent claudication: effective medical management of a common circulatory problem.
2001 Jun 28
The effects of pentoxifylline treatment on bacterial translocation after hemorrhagic shock in rats.
2001 Mar
Time-dependent influence of pentoxifylline on the pharmacokinetics of orally administered carbamazepine in human subjects.
2001 Mar
[The effect of pentoxifylline on the deformability of erythrocytes in erythrocyte concentrates in additive solution].
2001 Mar
[Pentoxifylline: is it useful in multiple sclerosis?].
2001 Mar 16-31
Controlled perfusion of the transplanted lung.
2001 May
Prophylactic use of pentoxifylline on inflammation in elderly cardiac surgery patients.
2001 May
Influence of prophylactic use of pentoxifylline on postoperative organ function in elderly cardiac surgery patients.
2001 May
Modulation of human peripheral blood mononuclear cell activation by the combination of leflunomide and pentoxifylline.
2001 May
A toast to pentoxifylline.
2001 May
Inhibitory effects of cyclic AMP elevating agents on lipopolysaccharide (LPS)-induced microvascular permeability change in mouse skin.
2001 May
A comparison of heat-induced hyperactivation in patients' sperm after colloid or pentoxifylline wash methods.
2001 May
Preventive effect of inhaled nitric oxide and pentoxifylline on ischemia/reperfusion injury after lung transplantation.
2001 May 15
The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation.
2001 May 18
Use of pentoxifylline in membranous nephropathy.
2001 May 26
Pentoxifylline: wonder drug?
2001 May-Jun
Patents

Sample Use Guides

The usual dosage of Pentoxil (Pentoxifylline Extended-release Tablets, USP) in extended-release tablet form is one tablet (400 mg) three times a day with meals. While the effect of Pentoxil may be seen within 2 to 4 weeks, it is recommended that treatment be continued for at least 8 weeks. Efficacy has been demonstrated in double-blind clinical studies of 6 months duration.
Route of Administration: Oral
The proliferation rate of the cells treated with 1 mM Pentoxifylline (PTX) significantly decreased compared with that of the control in T6 cells (78.3 ± 6.03% at 12 h, 61.0 ± 7.55% at 24 h, and 44.7 ± 2.08% at 48 h, p < 0.05). PTX (1 mM) also decreased the fraction of the hepatic stellate cells (HSC) population in the S and G2/M-phases of the cell cycle in primary activated rat HSCs. The Raf-1 inhibitor GW5074 and the ERK inhibitor U0126 had inhibitory effects that were similar to those of PTX on HSC proliferation. In addition, PTX inhibited the phosphorylation of Raf-1 (p-Raf-1) and ERK (p-ERK) in a dose- and time-dependent manner in HSCs.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:02:56 UTC 2021
Edited
by admin
on Fri Jun 25 21:02:56 UTC 2021
Record UNII
SD6QCT3TSU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PENTOXIFYLLINE
EP   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
PENTOXIFYLLINE [ORANGE BOOK]
Common Name English
PENTOXIFYLLINE [MART.]
Common Name English
NSC-637086
Code English
OXYPENTIFYLLINE
Common Name English
BL-191
Code English
TRENTAL
Brand Name English
PENTOXIFYLLINE [EP MONOGRAPH]
Common Name English
PENTOXIFYLLINE [VANDF]
Common Name English
PENTOXIFYLLINE [JAN]
Common Name English
PENTOXIL
Brand Name English
PENTOXIFYLLINE [USP-RS]
Common Name English
PENTOXIFYLLINE [INN]
Common Name English
C04AD03
Code English
1H-PURINE-2,6-DIONE, 3,7-DIHYDRO-3,7-DIMETHYL-1-(5-OXOHEXYL)-
Systematic Name English
NSC-758481
Code English
PENTOXIPHYLLIN
Common Name English
PENTOXIFYLLINE [USP MONOGRAPH]
Common Name English
PENTOXIFYLLINE [MI]
Common Name English
PENTOXIFYLLINE [WHO-DD]
Common Name English
BL 191
Code English
1-(5-OXOHEXYL)THEOBROMINE
Systematic Name English
PENTOXIFYLLINE [USAN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 369712
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
WHO-VATC QC04AD03
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
NDF-RT N0000009065
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
NCI_THESAURUS C744
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
NCI_THESAURUS C1327
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
NCI_THESAURUS C221
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
LIVERTOX 760
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
NDF-RT N0000175895
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
WHO-ATC C04AD03
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
Code System Code Type Description
INN
3309
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
PRIMARY
LACTMED
Pentoxifylline
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
PRIMARY
FDA UNII
SD6QCT3TSU
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
PRIMARY
MERCK INDEX
M8519
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
PRIMARY Merck Index
MESH
D010431
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
PRIMARY
CAS
6493-05-6
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
PRIMARY
EVMPD
SUB09705MIG
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
PRIMARY
PUBCHEM
4740
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
PRIMARY
RXCUI
8013
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
2099
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
PRIMARY
DRUG BANK
DB00806
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
PRIMARY
IUPHAR
7095
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
PRIMARY
ChEMBL
CHEMBL628
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
PRIMARY
EPA CompTox
6493-05-6
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
PRIMARY
NCI_THESAURUS
C733
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
PRIMARY
USP_CATALOG
1508901
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
PRIMARY USP-RS
WIKIPEDIA
PENTOXIFYLLINE
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
PRIMARY
ECHA (EC/EINECS)
229-374-5
Created by admin on Fri Jun 25 21:02:56 UTC 2021 , Edited by admin on Fri Jun 25 21:02:56 UTC 2021
PRIMARY
Related Record Type Details
EXCRETED UNCHANGED
URINE
Related Record Type Details
METABOLITE -> PARENT
METABOLITE ACTIVE -> PARENT
MINOR
METABOLITE ACTIVE -> PARENT
OCCURS DURING FIRST PASS METABOLISM
MAJOR
PLASMA
METABOLITE -> PARENT
METABOLITE INACTIVE -> PARENT
APPEARS TO OCCUR PREDOMINANTLY IN RED BLOOD CELLS THROUGH NADPH REDUCTASE ENZYMES
MAJOR
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION